Clinical Trials to Assess the Efficacy and Safety of HLIM

Last updated: February 7, 2019
Sponsor: SamA Pharmaceutical Co., Ltd
Overall Status: Active - Recruiting

Phase

3

Condition

Bronchitis

Respiratory Syncytial Virus (Rsv) Infection

Bronchitis (Pediatric)

Treatment

N/A

Clinical Study ID

NCT03827590
HLIM(SA16002)
  • Ages 2-75
  • All Genders

Study Summary

The purpose of this study is to assess the efficacy and safety of HLIM

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age between 2 and 75

  • Weight more than 11.5 kg

Exclusion

Exclusion Criteria:

  • Has a history of hypersensitivity to IP ingredients

  • Hypertension or Diabetes

  • Smoking more than 20 pack-years

Study Design

Total Participants: 487
Study Start date:
November 29, 2018
Estimated Completion Date:
October 31, 2019

Study Description

A randomized, double-blind, active-controlled, multicenter phase 3 clinical trial.

Connect with a study center

  • Korea University Guro Hospital

    Seoul, Guro-gu 08308
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.